TNFSF10 and hepatocellular carcinoma: Using different HCC cell lines and HCC tissues from various patients reflecting HCC heterogeneity, we investigated whether the sorafenib response could be enhanced by the combination with apoptosis-inducing or sensitizing agents, such as TRAIL or the BH3-mimetic ABT-737.